With An Additional Active Ingredient Patents (Class 514/479)
-
Publication number: 20110118117Abstract: A pesticide granule is provided that includes a base carrier particle. A liquid pesticide coating is applied to the particle surface. The coating may contain adjuvants. The coating has sufficient tack to adhere a second powdered pesticide to the carrier particle. The usage of tackifying agents to render the particle surface tacky enough to adhere powdered pesticide is reduced or eliminated. The powdered pesticide is sized to a mean diameter of less than 10% of the carrier diameter to promote adhesion. The synergistic rapid acting pesticide delivery associated with the granule results in the usage of less pesticide to control a given pest with reduced environmental impact. Bifenthrin is a representative of the liquid pesticide.Type: ApplicationFiled: January 3, 2011Publication date: May 19, 2011Inventors: Timothy D. Birthisel, James R. Lynch, Matthew G. Johnston
-
Publication number: 20110098253Abstract: The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders comprising administration of novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent.Type: ApplicationFiled: December 28, 2010Publication date: April 28, 2011Applicant: Nicox S.A.Inventors: Richard Earl, Maiko Ezawa, Xinquin Fang, David S. Garvey, Ricky D. Gaston, Subhash P. Khanapure, L. Gordon Letts, Chia-En Lin, Ramani R. Ranatunge, Stewart K. Richardson, Joseph D. Schroeder, Cheri A. Stevenson, Shiow-Jyi Wey
-
Publication number: 20110064804Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.Type: ApplicationFiled: April 9, 2010Publication date: March 17, 2011Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz
-
Publication number: 20110059114Abstract: Compositions and uses of gamma secretase inhibitors (GSIs) for the treatment and inhibition of gliomas in subjects in need thereof are provided. Methods for administering gamma secretase inhibitors in association with radiation for the treatment of radiation resistant gliomas are described. Compositions for the inhibition of Notch signaling and activity are provided.Type: ApplicationFiled: August 5, 2010Publication date: March 10, 2011Applicant: DUKE UNIVERSITYInventors: Bruce A. Sullenger, Jialiang Wang, Jeremy N. Rich
-
Publication number: 20110053914Abstract: A pharmaceutical combination comprising: (a) at least one 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol component and/or at least one 6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol component, and (b) at least one antiepileptic; a pharmaceutical composition comprising said combination, a medicament comprising such a combination, a kit containing the ingredients of such a combination, and a method of treating pain in which components (a) and (b) are administered simultaneously or sequentially, whereby component (a) may be administered before or after component (b), and in which components (a) and (b) are administered either via the same or a different pathway of administration.Type: ApplicationFiled: August 27, 2010Publication date: March 3, 2011Applicant: Gruenenthal GmbHInventors: Klaus SCHIENE, Petra Bloms-Funke
-
Publication number: 20110021502Abstract: The invention discloses the use of cholinesterase inhibitors in treating vascular depression.Type: ApplicationFiled: August 25, 2010Publication date: January 27, 2011Inventor: Roger Michael LANE
-
Publication number: 20110009483Abstract: Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid, pharmaceutical compositions thereof, methods of making prodrugs of trans-4-(aminomethyl)-cyclohexane-carboxylic acid, and methods of using prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof to treat or prevent various diseases or disorders are disclosed. Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof suitable for oral and topical administration and for administration using sustained release dosage forms are also disclosed.Type: ApplicationFiled: July 13, 2010Publication date: January 13, 2011Applicant: XenoPort, Inc.Inventors: Noa Zerangue, Bernd Jandeleit, Yunxiao Li, Mark A. Gallop
-
Publication number: 20110009268Abstract: The novel process for coacervating iodopropargyl compounds affords stable aqueous dispersions of coacervated iodopropargyl compounds which, optionally in a mixture with further active biocidal ingredients, can be used very effectively to protect technical materials.Type: ApplicationFiled: January 23, 2008Publication date: January 13, 2011Inventors: Hermann Uhr, Daniel Rudhardt, Frank Ridder, Johan Kijstra, Sascha Plug
-
Patent number: 7867507Abstract: A pesticide granule is provided that includes a base carrier particle. A liquid pesticide coating is applied to the particle surface. The coating may contain adjuvants. The coating has sufficient tack to adhere a second powdered pesticide to the carrier particle. The usage of tackifying agents to render the particle surface tacky enough to adhere powdered pesticide is reduced or eliminated. The powdered pesticide is sized to a mean diameter of less than 10% of the carrier diameter to promote adhesion. The synergistic rapid acting pesticide delivery associated with the granule results in the usage of less pesticide to control a given pest with reduced environmental impact. Bifenthrin is a representative of the liquid pesticide.Type: GrantFiled: November 3, 2006Date of Patent: January 11, 2011Assignee: The Andersons, Inc.Inventors: Timothy D. Birthisel, James R. Lynch, Matthew G. Johnston
-
USE OF POLYMERIC GUANIDINE DERIVATIVES FOR THE CONTROL OF UNWANTED MICROORGANISMS IN CROP PROTECTION
Publication number: 20110003689Abstract: The present invention relates to the use of polymeric guanidine derivatives for the curative and/or preventive treatment of unwanted microorganisms such as bacteria and phytopathogenic fungi in crop protection including the treatment of seed. The invention furthermore relates to novel active compound combinations comprising at least one polymeric guanidine derivative and at least one further fungicidally active compound, their use for the curative or preventive treatment of unwanted microorganisms in crop protection including the treatment of seed and not least the treated seed itself.Type: ApplicationFiled: December 6, 2008Publication date: January 6, 2011Applicant: AKA TECHNOLOGY GMBHInventors: Hans-Juergen Rosslenbroich, Arnd Voerste, Martin Schoepfer, Hilmar Wolf, Ulrike Wachendorff-Neumann, Peter Dahmen, Dirk Ebbinghaus, Oskar Schmidt -
Publication number: 20110002998Abstract: A process for the production of insecticide-modified bead material composed of expandable polystyrene (EPS) by extrusion, encompassing the steps of a) mixing, in a mixer, to incorporate a blowing agent and at least one insecticide from the group of the phenylpyrazoles, chlorfenapyr and hydramethylnon into a polymer melt which comprises at least one polystyrene, based on a vinylaromatic monomer, b) discharging the polymer melt comprising blowing agent, and c) pelletizing the polymer melt comprising blowing agent.Type: ApplicationFiled: December 5, 2008Publication date: January 6, 2011Applicant: BASF SEInventors: Michael Ishaque, Olaf Kriha, Carsten Schips, Norbert Güntherberg, Daniela Longo, Klaus Hahn, Bernhard Schmied, Clark D. Klein, Keith A. Holmes
-
Publication number: 20100323987Abstract: The invention relates to pharmaceutical combinations of retigabine and sodium channel inhibitors for treating, pains which are accompanied by an increase in muscle tone.Type: ApplicationFiled: August 30, 2010Publication date: December 23, 2010Applicant: Valeant Pharmaceuticals North AmericaInventors: Istvan SZELENYI, Kay BRUNE, Robert HERMANN, Mathias LOCHER
-
Publication number: 20100324075Abstract: Compounds, pharmaceutical compositions, and their methods of use in raising serum HDL levels in subjects in need thereof are provided. Also provided are compounds, pharmaceutical compositions, and their methods of use in increasing reverse cholesterol transport in subjects in need thereof. Finally, methods for treating disease by raising serum HDL levels and increasing reverse cholesterol transport are provided.Type: ApplicationFiled: December 19, 2008Publication date: December 23, 2010Applicant: UNIVERSITY OF CINCINNATIInventors: David Y. Hui, Philip N. Howles
-
Publication number: 20100311697Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.Type: ApplicationFiled: April 2, 2010Publication date: December 9, 2010Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz
-
Publication number: 20100311726Abstract: The present invention relates to novel uses for a family of small molecules, Differentiation-Inducing Factors (DIFs). It has been discovered that DIFs surprisingly can alter the metabolic processing of amyloid precursor protein (APP) and in turn reduce the level of secreted A?. The metabolic processing of other ?-secretase substrates normally present in cells (Notch and APLP1) is not affected when treated with DIF. The invention provides methods for reducing A? production in mammalian cells that express APP by administering DIF-I, DIF-2, DIF-3, a functionally equivalent analog and or any combination thereof. The invention also provides methods for treating and/or preventing Alzheimer's disease by preferentially reducing A? production.Type: ApplicationFiled: July 16, 2008Publication date: December 9, 2010Inventors: Michael Myre, Wilma Wasco, Rudolph E. Tanzi
-
Publication number: 20100311794Abstract: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.Type: ApplicationFiled: June 7, 2010Publication date: December 9, 2010Applicant: Gilead Sciences, Inc.Inventor: Chandrasekar Venkataramani
-
Publication number: 20100310680Abstract: This invention relates to a novel composition and method useful for the treatment of acne, and more particularly, to a composition and method for reducing an appearance of post acne marks and scars without skin irritation in a short amount of time.Type: ApplicationFiled: June 9, 2009Publication date: December 9, 2010Inventors: Theresa Chen, Geraldine Watson, I-Ting Wu
-
Publication number: 20100298335Abstract: This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.Type: ApplicationFiled: May 24, 2010Publication date: November 25, 2010Inventor: Herbert E. KAUFMAN
-
Publication number: 20100273874Abstract: The present invention relates to the novel use of Propineb as bird repellent.Type: ApplicationFiled: April 19, 2010Publication date: October 28, 2010Applicant: BAYER CROPSCIENCE AGInventors: Patrice DUVERT, Ralf Barfknecht
-
Patent number: 7816343Abstract: A wood preservative composition comprising a mixture of a fungicide which is a combination of a boric acid ester, which is soluble in an organic solvent and has a sterically hindered di-alcohol or tri-alcohol group, such as trihexylene glycol biborate, an organo-iodine compound, a triazole, and a synthetic pyrethroid insecticide, said fungicide and the insecticide being present in a sufficient amount that wood treated with the wood treatment material contains fungicide and insecticide in an amount of about 1 ppm to 5000 ppm, based on the weight of the wood after treatment.Type: GrantFiled: March 8, 2007Date of Patent: October 19, 2010Assignee: HWD Acquisition, Inc.Inventor: Mark C. Hoffman
-
Publication number: 20100256099Abstract: The invention provides a method of treatment of a human subject to combat infestation by multicellular ectoparasites with exoskeletons, in particular head lice, which method comprises topically applying to said subject a first and a second pediculicide, said first pediculicide being a carbamate or organophosphate pediculicide and said second pediculicide being a pyrethroid or pyrethrin pediculicide, characterized in that said second pediculicide is applied between 15 minutes and 12 hours after the application of said first pediculicide.Type: ApplicationFiled: July 16, 2008Publication date: October 7, 2010Applicant: NETTFORSK ASInventor: Baard Johannessen
-
Publication number: 20100234379Abstract: The endocannabinoid transporter and FAAH are sites of modulation that allow pharmacological enhancement of protective endocannabinergic signals. Selective inhibitors of the transporter and inhibitors of FAAH caused additive augmentation of endogenous signaling events mediated by the cannabinoid CB1 receptor. Disruption of such signals has been shown to prevent neuronal maintenance processes and increase vulnerability to brain damage. Here, blocking endocannabinoid inactivation enhanced cannabinergic activity and ameliorated cellular disturbances associated with excitotoxicity. Modulating the endocannabinoid system in this way also prevented excitotoxic behavioral abnormalities including memory impairment. Collectively, these results indicate that increasing endocannabinoid responses by inhibiting the endocannabinoid transported and/or the inhibiting FAAH leads to molecular, cellular, and functional protection against excitotoxic insults like stroke and traumatic brain injury.Type: ApplicationFiled: July 28, 2006Publication date: September 16, 2010Inventors: Ben A. Bahr, Alexandros Makriyannis, David A. Karanian
-
Patent number: 7772156Abstract: Microbicidal compositions including (a) cyanodithiocarbimate and (b) an N-alkyl heterocyclic compound; a triazole compound or salt thereof or metal complex thereof; a microbicide with an activated halogen atom or a formaldehyde releasing compound; 1,4-bis(bromoacetoxy)-2-butene; 2-(thiocyanomethylthio)benzothiazole; a methylene-bis(thiocyanate); a halogenated acetophenone; a halopropynl compound; an iodosulfone; a phenol; a halocyanoacetamide compound and/or a quaternary ammonium compound are described. Components (a) and (b) can be present in a synergistically effective amount to control the growth of at least one microorganism. Methods for controlling the growth of microorganisms with the compositions are also disclosed.Type: GrantFiled: November 1, 2006Date of Patent: August 10, 2010Assignee: Buckman Laboratories International, Inc.Inventor: Stephen D. Bryant
-
Publication number: 20100190752Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Applicant: Gruenenthal GmbHInventors: Klaus Schiene, Petra Bloms-Funke, Thomas Christoph
-
Publication number: 20100184707Abstract: The use of a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for manufacturing a pharmaceutical composition for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation.Type: ApplicationFiled: July 4, 2008Publication date: July 22, 2010Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Serge Picaud, Jose Alain Sahel, Jammoul Firas, Caroline Coriat, Manuel Simonutti
-
Publication number: 20100159032Abstract: The present invention provides a method for the treatment of neuronal disorders, in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of at least one QC-inhibitor, optionally in combination with at least one agent, selected from the group consisting of PEP-inhibitors, LiCl, inhibitors of DP IV/DP IV-like enzymes, NPY-receptor ligands, NPY agonists, NPY antagonists, ACE-inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases and inhibitors of neutral endopeptidase, to a mammal in need thereof.Type: ApplicationFiled: December 3, 2009Publication date: June 24, 2010Applicant: PROBIODRUG AGInventors: Ingo Schulz, Stephan Schilling, Hans-Ulrich Demuth, Ulrich Heiser, Andre Johannes Niestroj, Steffen Rossner
-
Publication number: 20100152287Abstract: Aqueous dispersion containing at least one iodopropargyl compound and at least one block and/or black copolymers on an ethylene and/or propylene oxide basis, having a numerically determined mean molecular weight greater than 1000 g/mol.Type: ApplicationFiled: May 19, 2008Publication date: June 17, 2010Applicant: LANXESS DEUTSCHLAND GMBHInventor: Hermann Uhr
-
Patent number: 7718822Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like.Type: GrantFiled: August 21, 2008Date of Patent: May 18, 2010Assignee: Sepracor Inc.Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
-
Publication number: 20100119609Abstract: Compositions, formulations, methods, and systems for treating thyroid eye disease and related conditions (e.g., Grave's Ophthalmopathy). The methods described herein include administering, to a patient in need, systemic or local beta adrenergic agonists (e.g., as an extended release crystalline microparticle suspension). The methods can further include administering a compound for reducing beta adrenergic receptor desensitization (e.g., a corticosteroid) prior to administering or coadministered with the beta adrenergic agonist. The methods can also include locally administering to the eye an immunosuppressant agent (e.g., rapamycin) prior to administering a beta adrenergic agonist. The compositions described herein include ophthalmic pharmaceutical formulations of beta adrenergic agonists in the form of extended release crystalline microparticle suspensions or mixtures of the crystalline microparticle suspensions with beta adrenergic agonist solutions.Type: ApplicationFiled: September 27, 2007Publication date: May 13, 2010Inventor: John Daniel Dobak
-
Publication number: 20100120744Abstract: The present invention relates to new acetamidopropane modulators of NMDA receptor, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: September 18, 2009Publication date: May 13, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Patent number: 7691377Abstract: A method for inhibiting melanoma cell growth in a patient by administering to the patient a therapeutically effective amount of a glutamate release inhibitor, a GRM1 antagonist, or a combination thereofType: GrantFiled: September 14, 2007Date of Patent: April 6, 2010Assignee: Rutgers, The State University of New JerseyInventors: James S. Goydos, Suzie Chen
-
Publication number: 20100076074Abstract: The present invention relates to new carbamate skeletal muscle relaxants, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: August 20, 2009Publication date: March 25, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manouchehr M. Shahbaz
-
Publication number: 20100063143Abstract: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on propamocarb-HCl, an insecticide active substance and optionally a further fungicide active substance.Type: ApplicationFiled: December 21, 2007Publication date: March 11, 2010Applicant: BAYER CROPSCIENCE AGInventors: Koen van Den Eynde, Wolfgang Thielert, Heike Hungenberg
-
Patent number: 7655695Abstract: Acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment are provided herein. The compounds described herein are useful as anti-neoplastic agents, i.e., to inhibit tumor cell growth in vitro or in vivo, in mammalian hosts, such as humans or animals, e.g., domestic animals, and are effective against solid tumors, hematologic malignancies and multi-drug resistant cancers/tumors. The present compounds can be used alone or they can be used in combination with one or more anti-cancer or anti-tumor agents.Type: GrantFiled: August 3, 2006Date of Patent: February 2, 2010Assignee: The Regents of The University of CaliforniaInventors: Trevor C. McMorris, Michael J. Kelner
-
Publication number: 20090324701Abstract: The present invention provides pharmaceutical compositions comprising (S)-bethanechol or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier and optionally at least one diabetes drug. The use of said composition in the treatment of insulin resistance, type 2 diabetes, impaired glucose tolerance and related disorders is also provided. The invention also provides for a kit comprising the pharmaceutical compositions and instructions for its use.Type: ApplicationFiled: January 19, 2007Publication date: December 31, 2009Applicant: DIAMEDICA, INC.Inventor: Mark Williams
-
Publication number: 20090306154Abstract: The present invention relates to the antimicrobial mixture comprising or consisting of: (a) one, two or more tropolone derivatives of the formula (1) wherein the substituents R1, R2, R3, R4, R5 independently of one another have the following meaning: H; linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; OH; OR6, wherein R6 is a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; COOH; COOR7, wherein R7 is a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; NO2, NH2, F, Cl, Br or I or salts or solvates thereof and (b) one or more compounds selected from the group consisting of: chlorphenesin, imidazolidinyl urea, DMDM hydantoin, ethylhexylglycerin, diazolidinyl urea, sodium hydroxymethylglycinate and polyaminopropyl biguanide or salts or solvates thereof.Type: ApplicationFiled: June 29, 2007Publication date: December 10, 2009Applicant: SYMRISE GMBH & CO., KGInventors: Ravikumar Pillai, Gerhard Schmaus
-
Publication number: 20090285862Abstract: The present invention relates to the field of pain management, and in particular, the management of inflammatory pain without inducing overt sedation. The present invention features compositions and treatments for inflammatory pain comprising the administration of an amount of an neurokinin (NK) antagonist in combination with a neuronal excitation inhibitor.Type: ApplicationFiled: May 3, 2007Publication date: November 19, 2009Applicant: CNSBio PTY LTD.Inventor: Colin Stanley Goodchild
-
Publication number: 20090233995Abstract: The present invention provides pharmaceutical compositions comprising: (a) a modulator of hepatic parasympathetic tone, (b) at least one diabetes drug, and (c) a pharmaceutically acceptable carrier. The present invention includes methods for the treatment and/or prevention of insulin resistance, type 2 diabetes, impaired glucose intolerance, and other associated disorders with pharmaceutical compositions described herein. The invention also provides for a kit comprising a pharmaceutical composition and instructions for its use.Type: ApplicationFiled: May 20, 2005Publication date: September 17, 2009Applicant: DiaMedica Inc.Inventor: Wilfred Wayne Lautt
-
Publication number: 20090215888Abstract: The present invention relates to a topical nail formulation comprising at least one active agent (e.g., tolnaftate) and at least one nail penetration enhancer selected from the group consisting of a fatty acid, an azone derivative, and mixtures thereof. The invention also relates to the use of said topical nail formulation for the treatment of nail disorders such as onychomycosis. The invention further provides a method of enhancing the nail flux of an active agent by using a topical nail formulation containing the said penetration enhancer.Type: ApplicationFiled: March 1, 2007Publication date: August 27, 2009Inventors: Singh Jagat, Dan McKay
-
Publication number: 20090131515Abstract: The combination of R-4-trimethylammonio-3-(tetra-decylcarbamoyl)-aminobutyrate and metformin is disclosed. Said combination of anti-diabetic drugs exerts a synergic action and allows the administration of the two drugs at doses such as to avoid or reduce the occurrence of side effects. The combination is also useful for improving the therapeutic cover far from mealtimes, and in postabsorption and fasting conditions.Type: ApplicationFiled: November 17, 2008Publication date: May 21, 2009Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.p.A.Inventors: Pompeo Pessoto, Fabio Giannessi
-
Patent number: 7534813Abstract: Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed.Type: GrantFiled: January 10, 2008Date of Patent: May 19, 2009Assignee: XenoPort, Inc.Inventors: Jia-Ning Xiang, Mark A. Gallop, Cindy X. Zhou, Mark Nguyen, Xuedong Dai, Jianhua Li, Kenneth C. Cundy, Nelson L. Jumbe
-
Publication number: 20090124574Abstract: The presently described embodiments are directed to compositions that include one or more carotenoid analogs or derivatives for use in the treatment of a disorder associated with platelet aggregation. Certain embodiments provide for the use of said carotenoid analogs or derivatives in preparing compositions suitable for use in such treatments. Further embodiments provide for pharmaceutical compositions that include one or more carotenoid analogs or derivatives in combination with one or more additional compositions or medicaments suitable for the treatment of a disorder associated with platelet aggregation.Type: ApplicationFiled: March 24, 2008Publication date: May 14, 2009Inventors: Samuel F. Lockwood, R. Preston Mason
-
Publication number: 20090088408Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics, processes for preparing them and their use in the treatment of respiratory diseases.Type: ApplicationFiled: August 29, 2008Publication date: April 2, 2009Inventors: Christopher J. M. Meade, Michel Pairet, Michael P. Pieper
-
Publication number: 20090005441Abstract: Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.Type: ApplicationFiled: June 25, 2008Publication date: January 1, 2009Applicant: Krele Pharmaceuticals, Inc.Inventor: Seth LEDERMAN
-
Publication number: 20080293676Abstract: Insecticidal compositions characterized by an effective amount of an active ingredient combination comprising (a) one or more compounds selected from the group of acetylcholinesterase inhibitors, sodium channel modulators, chitin biosynthesis inhibitors, juvenile hormone mimetics, chloride channel activators, ecdysone agonists, GABA-controlled chloride channel antagonists or acaricides, and (b) at least one crop plant tolerance promoter compound from the group of compounds specified in the description, which are used for controlling arthropods, and also methods of controlling arthropods through the treatment of plants and their seed with these compositions.Type: ApplicationFiled: July 18, 2005Publication date: November 27, 2008Applicant: BAYER CROPSCIENCE AGInventors: Reiner Fischer, Wolfram Andersch, Heike Hungenberg, Wolfgang Thielert, Lothar Willms
-
Patent number: 7449195Abstract: Fungicidal mixtures, comprising A) imidazole derivatives of the formula I ?in which R1 and R2 are halogen or phenyl, which may be substituted by halogen or alkyl, or R1 and R2 together with the bridging C?C double bond form a 3,4-difluoromethylenedioxyphenyl group; R3 is cyano or halogen, and R4 is dialkylamino or isoxazol-4-yl, which may carry two alkyl radicals; and B) valinamides of the formula II, ?in which R? is phenyl, which is substituted in the 4-position by halogen, C1-C4-alkyl or C1-C4-alkoxy, ?is 1- or 2-naphthyl, or ?is benzothiazol-2-yl, which is substituted in the 6-position by halogen; and R? is C3-C4-alkyl; in a synergistically effective amount, methods for controlling harmful fungi using mixtures of the compounds I and II and the use of the compounds I and the compounds II for preparing such mixtures are described.Type: GrantFiled: January 19, 2002Date of Patent: November 11, 2008Assignee: BASF AktiengesellschaftInventors: Arne Ptock, Eberhard Ammermann, Reinhard Stierl, Gisela Lorenz, Siegfried Strathmann, Maria Scherer, Klaus Schelberger, Achim Reddig
-
Publication number: 20080207713Abstract: The present invention is directed to compounds, combinations, compositions and methods for enhancing nitric oxide (NO) delivery to target sites, and in particular to muscle, both normal and dystrophic. Enhanced NO delivery according to the present invention may be achieved by using a combination of a muscle relaxant and an NO donor compound, or by using a compound of the invention: formula (I) wherein R1 is H, halo, C1-6 alkoxy or C1-6 alkyl; R2 is H, NO2 or C(O)NH2; R3 is H, NO2 or C(O)NH2; and at least one of R2 and R3 is NO2; or a pharmaceutically acceptable salt of the compound.Type: ApplicationFiled: June 8, 2006Publication date: August 28, 2008Inventors: Gu-Qi Wang, Frank J Burczynski, Judith E Anderson
-
Publication number: 20080200539Abstract: The present invention is a topical skin preparation for treatment of fungal infections of the skin and nails. The preparation comprises triacetin in combination with one or more antifungal agents. In a preferred form, the preparation comprises a combination of the antifungal agents tolnaftate and grisiofulvin are used in combination with triacetin. The concentrations of these constituents are 40 to 50% concentration triacetin, 30 to 50% acetone, 0.5-3.0% concentration tolnaftate and 0.5-4.0% concentration grisiofulvin, in one preferred embodiment. Other compounds, such as ethyl alcohol, acetone, amino acids such as n-acetylcysteine, and herbal additives may also be added to the preparation. Further, other antifungal agents such as nystatin, clortimazole, econazole, ketoconazole, miconazole, solconazole, oxiconizole, naftifine, terbinafine, and butenafine, for example, may be substituted for the antifungal agents tolnaftate and grisiofulvin.Type: ApplicationFiled: April 18, 2008Publication date: August 21, 2008Inventor: Alexander A. Bommarito
-
Publication number: 20080167312Abstract: Disclosed herein are substituted allylamines having structural Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and the methods of their use thereof.Type: ApplicationFiled: December 10, 2007Publication date: July 10, 2008Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20080161392Abstract: The invention relates to a liquid concentrate for the preservation of cosmetic an pharmaceutical prod nets which comprises 3-iodo-2-propynyl butylcarbamate (IPBC), at least on liquid carrier selected from the group consisting of: polyvalent alcohols, glycol esters and glycol ethers, and at least one stabilizer selected from the group consisting of: formic acid, formic acid salts, and format esters, and comprising no additional carboxylic acid selected from the group consisting of: benzoic acid, propionic acid, salicylic acid, sorbic acid, 4-hydroxybenzoic acid, dehydroacetic acid and 10-undecylenic acid and a salt thereof being present.Type: ApplicationFiled: March 17, 2008Publication date: July 3, 2008Applicant: L'AIR LIQUIDE SANTE (INTERNATIONAL)Inventors: Gisela Hahn, Klaus Weber, Ralf Gradtke, Wolfgang Beilfuss